DSM Firmenich (DSFIR) CMD 2024 summary
Event summary combining transcript, slides, and related documents.
CMD 2024 summary
31 Jan, 2026Strategic transformation and portfolio focus
Accelerated the separation of Animal Nutrition & Health (ANH) to focus on high-growth, high-margin consumer segments in nutrition, health, and beauty, with the ANH carve-out targeted for completion by end of 2025 and estimated separation costs of ~€100mn.
Portfolio review advanced to 2023, deprioritizing non-core and lower-growth segments such as non-differentiated vitamins, aroma ingredients, agro ingredients, yeast extracts, and marine lipids, totaling over €600 million in sales.
The new structure centers on three business units: Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care, each with clear mandates for value creation, growth, and profitability.
Accelerated integration and transformation, including the integration of DSM and Firmenich, with a focus on maximizing synergies and consumer-driven business.
Strategic focus is on science-backed innovation, sustainability, and leveraging global macro trends in holistic well-being.
Financial guidance and targets
Mid-term targets set at 5%-7% organic sales growth, 22%-23% adjusted EBITDA margin, and cash-to-sales conversion above 10%.
Dividend payout ratio reaffirmed at 40%-60% of earnings, with net debt/EBITDA maintained at 1.5-2.5x to protect investment-grade rating.
Pathway to targets includes ~1pp annual growth from synergies and another 1pp from portfolio tuning, building on a historical 4-5% organic growth rate.
EBITDA margin improvement driven by vitamin transformation, synergy delivery, and business unit acceleration, up from 18% in 2023.
CapEx to start at 6% of sales, normalizing to 5% post-major projects, with a focus on future-proofing growth and innovation.
Innovation, science, and sustainability
Over €700 million invested annually in R&D, with more than 2,000 innovation staff, 16,000+ patents, and over 100 science partnerships.
Key innovation platforms include bioscience, microbiome, and receptor/sensor technologies, powered by digital, data science, and AI.
Sustainability is a core driver, with targets to reduce carbon impact by 25% by 2030, achieve net zero by 2045, and ensure 100% responsible sourcing of key ingredients by 2030; 100% renewable electricity by 2025.
Employee engagement remains high at 80% during transformation and integration.
The business model combines ingredient toolbox, creation/innovation, and customer co-creation, underpinned by science and sustainability.
Latest events from DSM Firmenich
- Clear path to 4%-6% organic growth and 22%-23% EBITDA margin by 2028, driven by specialty focus.DSFIR
Investor update12 Mar 2026 - H1 2024 saw higher sales, EBITDA, and guidance, with strong P&B and TTH growth.DSFIR
H1 202410 Mar 2026 - 3% organic sales growth and resilient margins achieved despite ANH divestment and macro headwinds.DSFIR
Q4 202512 Feb 2026 - Divesting Animal Nutrition & Health for EUR 2.2bn, launching EUR 0.5bn buyback, and refocusing on core.DSFIR
Status update9 Feb 2026 - Separation of Animal Nutrition & Health set for 2025, targeting EUR 10B sales and >22% margins.DSFIR
Deutsche Bank’s Depositary Receipts Virtual Investor Conference20 Jan 2026 - Raised EBITDA outlook to €2.1bn on strong growth, synergies, and higher vitamin prices.DSFIR
Q3 2024 TU17 Jan 2026 - 2024 saw robust growth, margin expansion, and €2bn divestments, with a strong 2025 outlook.DSFIR
Q4 20248 Jan 2026 - Q1 2025 delivered 8% organic growth, 40% EBITDA rise, and major divestment and buyback actions.DSFIR
Q1 202525 Dec 2025 - Adjusted EBITDA up 29% and organic sales up 7%, with strong growth and portfolio actions.DSFIR
H1 20251 Nov 2025